Can Ozempic and Mounjaro Cure Addiction?

GLP-1 Drugs and Addiction: What the Early Research Actually Says

People on Ozempic keep reporting the same strange thing: they do more than lose their appetite for food. They lose interest in alcohol. Some say they stopped wanting to gamble. Others describe a general quieting of compulsive urges they have fought for years.

Anecdotes are not evidence. But when thousands of people report the same unexpected effect, researchers pay attention. And Dr. Mike Hansen, a pulmonologist and critical care physician with a strong track record of evidence-based content, digs into what we actually know so far.

GLP-1 Receptors Exist Beyond Your Gut

The story starts with biology. GLP-1 receptors are scattered throughout the brain, including in areas that regulate reward and motivation. The nucleus accumbens, the ventral tegmental area, the prefrontal cortex. These are the same circuits that light up during addictive behaviors, whether that is drinking, gambling, smoking, or binge eating.

When semaglutide or tirzepatide binds to GLP-1 receptors in these reward centers, it appears to dampen the dopamine response. The drug does not eliminate pleasure. It seems to reduce the intensity of craving, the pull that makes you reach for another drink or open that betting app one more time.

Hansen explains this carefully: the mechanism is plausible and the brain regions involved are well-documented. What we are still waiting for is large-scale human trial data.

Animal Studies Are Striking

In rodent models, GLP-1 agonists consistently reduce alcohol consumption, cocaine self-administration, and nicotine intake. Rats given semaglutide drink less alcohol when it is freely available. They show less interest in seeking out drugs they were previously addicted to.

These are not minor effects. Some studies show reductions of 40-60% in alcohol intake. The consistency across different addictive substances suggests the mechanism is not specific to one type of addiction but affects the reward circuitry more broadly.

Hansen is upfront about the limitation: what works in rodents does not always translate to humans. But the animal data is strong enough that multiple human clinical trials are now underway.

Human Data Is Early but Encouraging

Retrospective studies, which look back at patient records rather than running controlled experiments, have found that people on GLP-1 medications have lower rates of alcohol use disorder diagnoses and fewer alcohol-related hospitalizations compared to matched controls on other weight loss treatments.

A few small prospective studies have also shown promising results. Patients with alcohol use disorder who took semaglutide reported fewer heavy drinking days and lower alcohol cravings compared to placebo groups.

The numbers are still small. We are talking about studies with dozens to a few hundred participants, not the thousands typically needed for FDA-level evidence. But the signal is consistent across multiple research groups working independently.

What This Does Not Mean

Hansen makes a point that matters: nobody should take Ozempic as an addiction treatment right now. The FDA has not approved any GLP-1 drug for this purpose. Insurance will not cover it for addiction. And self-medicating with a drug that has its own side effect profile based on preliminary data is risky.

There is also a question about what happens when you stop the drug. If the anti-craving effect depends on active GLP-1 receptor stimulation, do cravings return when the medication stops? We do not know yet. It is a significant unknown.

The Brain Regions Doing the Heavy Lifting

The nucleus accumbens is the brain's primary reward center. When you eat something delicious, have a drink, or win a bet, dopamine floods this area. Over time, addictive substances hijack the system, making the nucleus accumbens respond more intensely to the drug than to normal rewards.

The ventral tegmental area (VTA) is the factory that produces much of that dopamine. It sends dopamine-releasing neurons directly to the nucleus accumbens. GLP-1 receptors are present on neurons in both of these regions, which gives semaglutide a direct line into the reward circuit.

When semaglutide binds to GLP-1 receptors in the VTA, it appears to reduce dopamine release in response to rewarding stimuli. The result is not numbness. It is more like turning the volume down on cravings. You can still enjoy things, but the compulsive pull loses some of its grip.

The prefrontal cortex matters too. This region handles impulse control, the part of your brain that says "I should not have another drink" while the nucleus accumbens screams "yes you should." GLP-1 receptor activity here may strengthen that braking system.

Why Your Doctor Is Not Prescribing Ozempic for Addiction Yet

Despite the promising signals, there are solid reasons no doctor is writing semaglutide prescriptions for alcohol use disorder or gambling addiction today.

The FDA requires large randomized controlled trials before approving a drug for a new indication. For addiction, those trials are just getting started at institutions like UNC and the NIH, with most results not expected until 2026 or 2027. Until then, prescribing GLP-1 drugs for addiction is off-label and legally risky.

Insurance is another barrier. Even if a doctor wanted to prescribe it for alcohol use disorder, insurers will not cover it for that purpose. At over $1,000 per month retail, most patients cannot afford it out of pocket.

There are also unanswered questions about dose. The amounts used for weight loss may not be right for addiction. Brain concentrations needed to modulate reward circuits could differ from what suppresses appetite.

And addiction is rarely a single-mechanism problem. Even if GLP-1 drugs prove effective, they will likely be one tool in a toolkit rather than a standalone cure.

Questions to Ask Your Doctor About GLP-1 Drugs and Addiction

If you are on a GLP-1 medication and have noticed changes in your relationship with alcohol, gambling, or other compulsive behaviors, it is worth bringing this up at your next appointment. Here are specific questions that can lead to a productive conversation.

"I have noticed my cravings for alcohol have decreased since starting semaglutide. Is this consistent with what other patients report?" This opens the door without making any claims about the drug being a treatment for addiction.

"Should I adjust my approach to alcohol while on this medication?" GLP-1 drugs slow gastric emptying, which changes how your body absorbs alcohol. You may get intoxicated faster on less alcohol. That is a practical safety concern, separate from the craving question.

"If my cravings return after stopping the medication, what options do we have?" This is forward-thinking and helps your doctor plan for the long term rather than reacting to a crisis.

"Are there any clinical trials for GLP-1 drugs and addiction that I might be eligible for?" If you have both obesity and an alcohol or substance use issue, you could be an ideal candidate. The NIH Clinical Trials registry (clinicaltrials.gov) lists active studies, and your doctor may know of local options.

How This Compares to Other Addiction-Related Content in the FormBlends Library

Hansen's video focuses on the neuroscience of reward circuits, which makes it a strong companion to the Institute of Human Anatomy video on what Ozempic does to the body. That video uses cadaver dissections to show the physical brain structures Hansen is describing here, including the nucleus accumbens and VTA. Watching both gives you both the conceptual framework and the anatomical reality.

The mental health effects video featuring Dr. Josef, a psychiatrist, covers overlapping territory from a different angle. Where Hansen asks "can GLP-1 drugs reduce addictive cravings?", Josef asks "can they affect your emotional relationship with food and other rewards?" The two videos together paint a more complete picture of how these drugs interact with your brain's reward and emotional regulation systems.

If you are interested in the food-specific side of reward reduction, the muscle preservation video from Dr. Dan addresses the practical challenge that comes with suppressed appetite: making sure reduced food intake does not cost you lean mass.

Real-World Implications for People Considering GLP-1 Therapy

For someone with both obesity and a substance use issue, this research opens a genuinely interesting possibility. Current addiction treatments have mixed success rates. Naltrexone, the most commonly prescribed medication for alcohol use disorder, reduces heavy drinking days by about 25% compared to placebo. If semaglutide can match or exceed that while also addressing obesity, it could become part of a dual-benefit treatment approach.

But the practical reality right now is complicated. If you tell your doctor you want Ozempic for alcohol cravings, they cannot prescribe it for that reason. Insurance will not cover it. The off-label path is possible if you also meet criteria for weight management, but that depends on your BMI and health history.

The people most likely to benefit right now are those who qualify for GLP-1 therapy on its own merits, for weight loss or diabetes, and happen to also struggle with compulsive behaviors. For them, the anti-craving effect is a welcome bonus, not a primary prescription reason. That may change in 3-5 years as trial data matures, but for now, the addiction benefit is a secondary finding rather than an approved indication.

Why This Matters Beyond Weight Loss

Addiction treatment has not seen a genuinely new pharmacological approach in decades. If GLP-1 drugs prove effective for alcohol use disorder, opioid cravings, or gambling addiction, that would be a major shift in how we think about both these medications and addiction itself.

It would also reframe what GLP-1 drugs are. They would more than be weight loss drugs that happen to help with cravings. They would be drugs that modulate reward circuitry, with weight loss being one of several therapeutic applications.

Hansen keeps his conclusion grounded: the data is exciting, the biology makes sense, and the early results are promising. But we are probably 3 to 5 years away from having the kind of evidence needed to change clinical practice.

For now, if you are on a GLP-1 medication and have noticed your interest in alcohol or other compulsive behaviors fading, you are not imagining it. And science is starting to explain why.